Compare BHAT & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BHAT | PMVP |
|---|---|---|
| Founded | 2010 | 2013 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.1M | 68.9M |
| IPO Year | 2019 | 2020 |
| Metric | BHAT | PMVP |
|---|---|---|
| Price | $1.24 | $1.23 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 39.8K | ★ 236.0K |
| Earning Date | 12-22-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $18,724,190.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.07 | $0.81 |
| 52 Week High | $24.50 | $1.84 |
| Indicator | BHAT | PMVP |
|---|---|---|
| Relative Strength Index (RSI) | 35.19 | 37.84 |
| Support Level | $1.07 | $1.30 |
| Resistance Level | $1.37 | $1.36 |
| Average True Range (ATR) | 0.09 | 0.08 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 32.16 | 0.00 |
Blue Hat Interactive Entertainment Technology is focused on commodity trading, including chemicals, jewelry, and precious metals such as gold. It operates a gold and diamond trading and supply chain business. Its business model encompasses physical gold trading, diamond trading, gold derivatives trading, and the development of AI-enabled trading platforms. Its segments include Diamond trading, Commodity trading, Information service, Interactive toys - animation series, and Interactive toys - game series. It derives revenue from Diamond trading. The majority of its revenues are generated in PRC.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.